ArticleAnnals of translational medicine2020
Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease.Nutrients · 2022Trial
- MMP-9 and non-invasive markers in evaluating MASLD and atherosclerosis.Journal, genetic engineering & biotechnology · 2026Article
- Association of Domain-Specific Physical Activities with Non-Alcoholic Fatty Liver Disease in Workers: A Focus on Gender Differences.Metabolites · 2026Article
- Steatotic liver disease indices for cardiovascular event prediction: Panasonic cohort study 28.American journal of preventive cardiology · 2026Article
- Association of MASLD with chronic kidney disease according to metabolic profiles and fibrosis severity: a KNHANES analysis.Frontiers in endocrinology · 2026Article
- Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.Scientific reports · 2025Article
- Development and validation of an online nomogram for screening metabolic-associated fatty liver disease in obese children.Italian journal of pediatrics · 2025Article
- A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients.Journal of diabetes investigation · 2025Article
- Evaluation of ten diagnostic models for metabolic dysfunction-associated fatty liver disease in lean people living with HIV.BMC infectious diseases · 2025Article
- Machine learning-based identification of biochemical markers to predict hepatic steatosis in patients at high metabolic risk.World journal of gastroenterology · 2025Article
- Is UA/HDL-C a Reliable Surrogate Marker for Fatty Liver? A Comparative Evaluation with Metabolic Scores in a Mexican Population: The Genetics of Atherosclerotic Disease Study.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults.BMC gastroenterology · 2025Article
- Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors.Frontiers in medicine · 2025Article
- Epidemiology and diagnostic of MASLD in Latin America: a yet to be met challenge.Frontiers in pharmacology · 2025Review
- Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study.BMC gastroenterology · 2024Article
- Article
- Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients.Diabetes & metabolism journal · 2024Article
- Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies.Journal of clinical and translational hepatology · 2023Review
- Article
- The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is estimated to affect approximately 30% population worldwide. However, there is yet a basic and generally implementable approach to define individuals at risk for NAFLD estimative of metabolic risk.
methodsTotal of 3,634 general participants without history of liver disease and alcohol consumption who received the Korean National Health and Nutrition Examination Survey between 2008 and 2010 were studied. Logistic regression was used to identify significant covariates indicative of NAFLD. Multivariable-adjusted logistic regression was carried out for evaluation on estimative impact of the derived score on metabolic risks.
resultsSex [female; odd ratio (OR), 2.492; 95% confidence interval (CI), 1.921-3.233; P<0.001], waist circumference (WC) (OR, 1.093; 95% CI, 1.077-1.110, P<0.001) systolic blood pressure (OR, 1.033; 95% CI, 1.025-1.040; P<0.001), fasting serum glucose (FSG) (OR, 1.032; 95% CI, 1.026-1.038; P<0.001), triglyceride (OR, 1.007; 95% CI, 1.006-1.009; P<0.001), and alanine aminotransferase (OR, 1.110; 95% CI, 1.097-1.124; P<0.001) were independently indicative of NAFLD, which constituted the derived scoring system. The system revealed a significant correlation with the NAFLD liver fat score, fatty liver index (FLI), body mass index, age, alanine aminotransferase, and triglycerides (BAAT) score, lipid accumulation product, and hepatic steatosis index. In addition, the derived score was significantly estimative of insulin resistance.
conclusionsThe developed score may be supportive of stratification of individuals at high risk of NAFLD, non-invasive fast diagnosis of NAFLD, and estimation of metabolic risk. Future studies that compare the derived score with standard diagnostic tests-validated data, such as ultrasonography of the liver, are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.